Home/Pipeline/PMN442

PMN442

Amyotrophic Lateral Sclerosis (ALS)

PreclinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Preclinical

Status

Active

Company

ProMIS Neurosciences

About ProMIS Neurosciences

ProMIS Neurosciences is dedicated to developing precision antibody therapies for neurodegenerative diseases by selectively targeting toxic misfolded protein oligomers. Its core achievement is the EpiSelect™ computational discovery platform, which has generated a pipeline of candidates, including PMN310 for Alzheimer's disease, now in a Phase 1b trial. The company's strategy is to demonstrate a differentiated safety and efficacy profile by sparing non-toxic protein forms, aiming to advance directly into registrational studies. A recent $175 million financing provides a cash runway through 2027 to execute this plan.

View full company profile

Therapeutic Areas

Alzheimer's Disease Amyotrophic Lateral Sclerosis Parkinson's Disease Multiple System Atrophy Frontotemporal Dementia

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active
NG CELL	NeuroGenesis Bio	Phase 2	Active
NP001	Neuvivo	Phase 3	Active
BREN02 / hEN1	BrainEver	Pre-clinical	Active